APIMEDS PHARMACEUTICALS US I (APUS) Stock Price & Overview
NYSEARCA:APUS • US03771D1028
Current stock price
The current stock price of APUS is 1.88 USD. Today APUS is up by 7.43%. In the past month the price decreased by -85.54%.
APUS Key Statistics
- Market Cap
- 23.65M
- P/E
- N/A
- Fwd P/E
- N/A
- EPS (TTM)
- -1.20
- Dividend Yield
- N/A
APUS Stock Performance
APUS Stock Chart
APUS Technical Analysis
ChartMill assigns a technical rating of 0 / 10 to APUS.
APUS Fundamental Analysis
ChartMill assigns a fundamental rating of 3 / 10 to APUS. While APUS has a great health rating, there are worries on its profitability.
APUS Earnings
APUS Forecast & Estimates
APUS Groups
Sector & Classification
APUS Financial Highlights
Over the last trailing twelve months APUS reported a non-GAAP Earnings per Share(EPS) of -1.2. The EPS decreased by -79.1% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -13.18% | ||
| ROE | -14.27% | ||
| Debt/Equity | 0 |
APUS Ownership
APUS Competitors/Peers
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABBV | ABBVIE INC | 14.09 | 371.899B | ||
| AMGN | AMGEN INC | 15.31 | 189.187B | ||
| GILD | GILEAD SCIENCES INC | 15.94 | 174.329B | ||
| VRTX | VERTEX PHARMACEUTICALS INC | 22.7 | 113.007B | ||
| REGN | REGENERON PHARMACEUTICALS | 16.18 | 79.873B | ||
| ALNY | ALNYLAM PHARMACEUTICALS INC | 49.2 | 45.013B | ||
| INSM | INSMED INC | N/A | 33.111B | ||
| NTRA | NATERA INC | N/A | 30.421B | ||
| RVMD | REVOLUTION MEDICINES INC | N/A | 29.133B | ||
| BIIB | BIOGEN INC | 11.12 | 26.264B | ||
| UTHR | UNITED THERAPEUTICS CORP | 19.89 | 25.357B | ||
| MRNA | MODERNA INC | N/A | 20.956B | ||
| INCY | INCYTE CORP | 12.76 | 19.441B |
Related stock screener links
View all stocks in the Biotechnology Industry | View all stocks in the Health Care Sector | View all stocks on the NYSE Arca Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
About APUS
Company Profile
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
Company Info
IPO: 2025-05-09
APIMEDS PHARMACEUTICALS US I
100 Matawan Road, Suite 325
Matawan NEW JERSEY US
Employees: 2
Phone: 18009279800
APIMEDS PHARMACEUTICALS US I / APUS FAQ
What does APIMEDS PHARMACEUTICALS US I do?
Apimeds Pharmaceuticals US, Inc. is a clinical stage biopharmaceutical company that engages in the development of Apitox, an intradermally administered bee venom-based toxin. The company is headquartered in Matawan, New Jersey and currently employs 2 full-time employees. The company went IPO on 2025-05-09. The firm is engaged in developing Apitox, an intradermally administered bee venom-based toxin. The company is focused on developing Apitox in the treatment of inflammatory conditions in the United States, specifically osteoarthritis and multiple sclerosis. Its subsidiary, MindWave Innovations Inc, is a provider of institutional digital asset treasury (DAT) solutions.
What is the stock price of APIMEDS PHARMACEUTICALS US I today?
The current stock price of APUS is 1.88 USD. The price increased by 7.43% in the last trading session.
Does APIMEDS PHARMACEUTICALS US I pay dividends?
APUS does not pay a dividend.
What is the ChartMill rating of APIMEDS PHARMACEUTICALS US I stock?
APUS has a ChartMill Technical rating of 0 out of 10 and a ChartMill Fundamental rating of 3 out of 10.
How is the valuation of APIMEDS PHARMACEUTICALS US I (APUS) based on its PE ratio?
APIMEDS PHARMACEUTICALS US I (APUS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-1.2).
Can you provide the market cap for APIMEDS PHARMACEUTICALS US I?
APIMEDS PHARMACEUTICALS US I (APUS) has a market capitalization of 23.65M USD. This makes APUS a Nano Cap stock.